What the label lists and what reports show
Adalimumab-adbm side effects
Adalimumab-adbm's FDA label: “Most common adverse reactions (>10%) are: infections (e.g., upper respiratory, sinusitis), injection site reactions, headache and rash.” FAERS holds 213 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is device malfunction (23 reports).
- No generic listed
- Boxed warning
Check it at the source: the adalimumab-adbm FDA label on DailyMed (effective May 22, 2026, Boehringer Ingelheim Pharmaceuticals, Inc.); the FDA FAERS public dashboard.
What does the patient leaflet say about side effects?
From the patient leaflet: What are the possible side effects of CYLTEZO?CYLTEZO can cause serious side effects, including: See " What is the most important information I should know about CYLTEZO? " Serious Infections. Your doctor will examine you for TB and perform a test to see if you have TB. If your doctor feels that you are at risk for TB, you may be treated with medicine for TB before you begin treatment with CYLTEZO and during treatment with CYLTEZO. Even if your TB test is negative your doctor should carefully monitor you for TB infections while you are taking CYLTEZO. People who had a negative TB skin test before receiving adalimumab products have developed active TB. Tell your doctor if you have any of the following symptoms while taking or after taking CYLTEZO: cough that does not go away low grade fever weight loss loss of body fat and muscle (wasting) Hepatitis B infection in people who carry the virus in their blood. […]
Source: FDA drug label, Boehringer Ingelheim Pharmaceuticals, Inc., effective May 22, 2026 (SPL set 115ea79b-7209-7f19-b35d-36ec0828fbf5), via openFDA; the full label on DailyMed
What does the label list?
From the label: adverse reactionsMost common adverse reactions (>10%) are: infections (e.g., upper respiratory, sinusitis), injection site reactions, headache and rash.
Table 1. Adverse Reactions Reported by ≥5% of Subjects Treated with Adalimumab During Placebo-Controlled Period of Pooled RA Studies (Studies RA-I, RA-II, RA-III, and RA-IV)
| Reaction | Adalimumab 40 mg subcutaneous Every Other Week (N=705) | Placebo (N=690) |
|---|---|---|
| Upper respiratory infection | 17% | 13% |
| Sinusitis | 11% | 9% |
| Flu syndrome | 7% | 6% |
| Nausea | 9% | 8% |
| Abdominal pain | 7% | 4% |
| Laboratory test abnormal | 8% | 7% |
| Hypercholesterolemia | 6% | 4% |
| Hyperlipidemia | 7% | 5% |
| Hematuria | 5% | 4% |
| Alkaline phosphatase increased | 5% | 3% |
| Headache | 12% | 8% |
| Rash | 12% | 6% |
| Accidental injury | 10% | 8% |
| Injection site reaction | 8% | 1% |
| Back pain | 6% | 4% |
| Urinary tract infection | 8% | 5% |
| Hypertension | 5% | 3% |
Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.
From the label: adverse reactions, continuedThe following clinically significant adverse reactions are described elsewhere in the labeling: Serious Infections [see Warnings and Precautions (5.1) ] Malignancies [see Warnings and Precautions (5.2) ] Hypersensitivity Reactions [see Warnings and Precautions (5.3) ] Hepatitis B Virus Reactivation [see Warnings and Precautions (5.4) ] Neurologic Reactions [see Warnings and Precautions (5.5) ] Hematological Reactions [see Warnings and Precautions (5.6) ] Heart Failure [see Warnings and Precautions (5.8) ] Autoimmunity [see Warnings and Precautions (5.9) ] Most common adverse reactions (>10%) are: infections (e.g., upper respiratory, sinusitis), injection site reactions, headache and rash. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most common adverse reaction with adalimumab was injection site reactions. …
Source: FDA drug label, Boehringer Ingelheim Pharmaceuticals, Inc., effective May 22, 2026 (SPL set 115ea79b-7209-7f19-b35d-36ec0828fbf5), via openFDA; the full label on DailyMed
What do FAERS reports show?
213 reports list adalimumab-adbm among the medicines taken, each a report of something that happened, not proof the medicine caused it; 2 are coded as a death and 21 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 18 reactions below, 7 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Adalimumab-adbm: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions